Biorestorative Therapies (BRTX) Expected to Post Earnings on Tuesday

Biorestorative Therapies (NASDAQ:BRTX) is expected to be posting its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.60 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Biorestorative Therapies (NASDAQ:BRTX) last posted its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.31 million. Biorestorative Therapies had a negative return on equity of 508.42% and a negative net margin of 3,088.27%. On average, analysts expect Biorestorative Therapies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Biorestorative Therapies Stock Performance

Biorestorative Therapies stock traded up $0.02 during midday trading on Tuesday, reaching $0.21. 122,863 shares of the company were exchanged, compared to its average volume of 8,445,541. The firm’s 50-day simple moving average is $0.36 and its 200-day simple moving average is $0.40. Biorestorative Therapies has a 1 year low of $0.16 and a 1 year high of $1.89. The company has a market capitalization of $5.45 million, a price-to-earnings ratio of -0.20 and a beta of 0.79.

Hedge Funds Weigh In On Biorestorative Therapies

Several institutional investors and hedge funds have recently bought and sold shares of BRTX. Citadel Advisors LLC purchased a new stake in shares of Biorestorative Therapies during the 3rd quarter valued at $152,000. DRW Securities LLC acquired a new stake in shares of Biorestorative Therapies during the 4th quarter worth $55,000. Finally, Virtu Financial LLC raised its position in shares of Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after buying an additional 12,319 shares during the period. Institutional investors and hedge funds own 69.38% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biorestorative Therapies currently has a consensus rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.